

A stylized world map in shades of blue is positioned at the top left. Below it, a series of vertical blue bars of varying heights are set against a background of blue arches that recede into the distance.

ESSENTIAL MESSAGES FROM ESC GUIDELINES

Committee for Practice Guidelines

To improve the quality of clinical practice and patient care in Europe



AMI - STEMI

For more information

www.escardio.org/guidelines



ESC ESSENTIAL MESSAGES

ESC GUIDELINES ON THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH STEMI*

The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology

Chairperson:

Frans Van de Werf

Department of Cardiology
University Hospitals Leuven
Herestraat 49
B-3000 Leuven, Belgium

Email: frans.vandewerf@uzleuven.be

Task Force Members:

1. Jeroen Bax, The Netherlands
2. Amadeo Betriu, Spain
3. Carina Blomstrom-Lundqvist, Sweden
4. Filippo Crea, Italy
5. Volkmar Falk, Germany
6. Gerasimos Filippatos, Greece
7. Keith Fox, UK
8. Kurt Huber, Austria
9. Adnan Kastrati, Germany
10. Annika Rosengren, Sweden
11. P. Gabriel Steg, France
12. Marco Tubaro, Italy
13. Freek Verheugt, The Netherlands
14. Franz Weidinger, Austria
15. Michael Weis, Germany

ESC Staff:

1. Keith McGregor, Sophia Antipolis, France
2. Veronica Dean, Sophia Antipolis, France
3. Catherine Després, Sophia Antipolis, France

Special thanks to Professor Dr Sigmund Silber for his contribution

ESSENTIAL MESSAGES FROM ESC GUIDELINES ON THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH STEMI

Table of contents

-  Section 1 - Take home messages
-  Section 2 - Major gaps in evidence

Take home messages

- 1.** Very early reperfusion of the occluded infarct artery is the mainstay in the treatment of an acute myocardial infarction with persistent ST-segment elevation (STEMI).
- 2.** Pre-hospital (ambulance) clinical and ECG diagnosis is critical for reducing the time delays between onset of symptoms and start of reperfusion. This can best be achieved by establishing a network of non-PCI-capable and PCI-capable (24h/7d) hospitals connected by an efficient ambulance service.
- 3.** Primary PCI with stenting, when performed by an experienced team within the recommended time, is the best reperfusion treatment to save lives.
- 4.** Primary PCI should be performed within 120 min after ECG diagnosis (first medical contact) in all patients and within 90 min in patients presenting within 2 hours and with a large infarct.
- 5.** If primary PCI cannot be performed within the recommended time, fibrinolytic therapy (preferably with a fibrin-specific agent) should be started as soon as possible, already in the ambulance.
- 6.** In the absence of contra-indications, all patients should receive aspirin, a thienopyridine (clopidogrel or prasugrel) and one of the following anticoagulants as soon as possible: bivalirudin or heparin, if primary PCI will be performed; enoxaparin or heparin, if a fibrin-specific lytic agent is given; fondaparinux, enoxaparin or heparin, if streptokinase is given.
- 7.** In case of failed fibrinolytic therapy, rescue PCI should be performed, if infarct size is large and if the procedure can be done within 12h after onset of symptoms.
- 8.** After successful fibrinolysis, transfer to a PCI capable hospital for coronary angiography, ideally between 3 to 24 hours after start of fibrinolytic therapy, is indicated in most patients.
- 9.** Anticoagulant therapy should be stopped shortly after the PCI procedure or after 24 to 48 hours in case of fibrinolytic therapy.
- 10.** An oral ACE-inhibitor should be given on the first day in the absence of contra-indications in patients with significant LV dysfunction.
- 11.** Routine i.v. administration of a beta-blocker is not indicated. An oral beta-blocker should be given as soon as the patient is stable.

Take home messages

12. Statins should be initiated as soon as possible to achieve an LDL cholesterol < 100 mg/dL (2.5 mmol /L) or < 80 mg (2.5 mmol/L) if feasible irrespective of the initial cholesterol level. Risk factors for atherosclerosis should be identified and treatment started before hospital discharge.

13. At discharge and in the absence of contra-indications, all patients should be treated with ASA, a thienopyridine, a beta-blocker and a statin; in patients with significant LV dysfunction, an ACE-inhibitor (or an ARB) should be added. With the exception of the thienopyridine, these medications should be given forever.

Major gaps in evidence

There is limited experience with PCI in STEMI patients presenting later than 12h after onset of symptoms.

Transporting patients from a non-PCI-capable to a PCI-capable hospital for primary PCI remains a challenge. Even in the best networks many patients are treated with PCI outside the recommended time window. It is unknown whether pre-hospital fibrinolysis during transport to a PCI-capable hospital in patients presenting early to the EMS (emergency medical system) is beneficial if the intervention cannot be performed within the recommended time window.

Cardiologists in some hospitals are still uncertain which pharmacological treatment to start before transport.

A number of patients need oral anticoagulation after primary PCI with stenting. Whether ASA and/or a thienopyridine added to an oral anticoagulant are effective and safe in all patients, is unknown as is the optimal duration of these antithrombotic regimen.

Long-term beta-blockade post-STEMI was studied in the pre-reperfusion era . The evidence for routine long-term use of a beta-blocker in STEMI patients with preserved left ventricular function after successful reperfusion is not well documented.



**EUROPEAN
SOCIETY OF
CARDIOLOGY®**

EUROPEAN SOCIETY OF CARDIOLOGY
2035, ROUTE DES COLLES
LES TEMPLIERS - BP 179
06903 SOPHIA ANTIPOLIS CEDEX - FRANCE
PHONE: +33 (0)4 92 94 76 00
FAX: +33 (0)4 92 94 76 01
E-mail: guidelines@escardio.org

To read the parent document as published by the European Society of Cardiology, visit our web site at: www.escardio.org/guidelines

Copyright © European Society of Cardiology 2009 - All Rights Reserved.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to ESC, Practice Guidelines Department, 2035, route des Colles - Les Templiers - BP179 - 06903 Sophia Antipolis Cedex - France.

Disclaimer:

The ESC Guidelines represent the views of the ESC which were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgment. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient's guardian or carer. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

For more information

www.escardio.org/guidelines